Joint Free Advanced
Natural health product licensed in Canada
- Licence holder
- Sancta Health Canada Inc.
- NPN or DIN-HM
- 80085746
- Status
- Active licence
- Licence date
- 31 May 2018
- Revision date
- Not provided
- Form
- Capsule, dur
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Chlorhydrate de 2-amino-2-désoxy-bêta-D-glucopyranose Source : Exosquelette de crevette | 375 milligramme | Not calculated |
| Chlorhydrate de 2-amino-2-désoxy-bêta-D-glucopyranose Source : Exosquelette de crabe | 375 milligramme | Not calculated |
| Sulfate de chondroïtine Source : Bos taurus - cartilage | 50 milligramme | Not calculated |
| Acide hyaluronique Source : Streptococcus equi - capsule extracellulaire bactérienne | 825 microgrammes | Not calculated |
| Senegalia catechu Source : Stem heartwood Extract : Matériel brut sec Extraction ratio : 20:1 Dry plant equivalent : 425 milligramme | 21.25 milligramme | Not calculated |
| Scutellaria baicalensis Source : Racine Extract : Matériel brut sec Extraction ratio : 15:1 Dry plant equivalent : 1,500 milligramme Potency : 75 % Baicalin | 100 milligramme | Not calculated |
Non-medicinal ingredients
Gélatine, Stéarate de magnésium, Crospovidone, Maltodextrine, Silice, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 2 Capsule | 2 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Univestin® helps to relieve joint discomfort, stiffness and to improve mobility in persons suffering from osteoarthritis. Univestin® clinically proven to help improve decreased range of motion associated with osteoarthritis of the knee in 7 days. Univestin® starts to help to relieve joint discomfort associated with osteoarthritis of the knee in 5 days. Univestin® starts to help to reduce joint stiffness associated with osteoarthritis of the knee in 3 days. Provides antioxidants that help protect cell against the oxidative damage caused by free radicals.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80085746
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.